{"organizations": [], "uuid": "1243b1502a2070d2e910f4b1b5bc680734c98caf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180514.html", "section_title": "Archive News &amp; Video for Monday, 14 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-chiasma-announces-fda-agreement-to/brief-chiasma-announces-fda-agreement-to-redefine-certain-secondary-endpoints-in-phase-3-clinical-trial-idUSASC0A22I", "country": "US", "domain_rank": 408, "title": "BRIEF-Chiasma Announces FDA Agreement To Redefine Certain Secondary Endpoints In Phase 3 Clinical Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.078, "site_type": "news", "published": "2018-05-15T04:23:00.000+03:00", "replies_count": 0, "uuid": "1243b1502a2070d2e910f4b1b5bc680734c98caf"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-chiasma-announces-fda-agreement-to/brief-chiasma-announces-fda-agreement-to-redefine-certain-secondary-endpoints-in-phase-3-clinical-trial-idUSASC0A22I", "ord_in_thread": 0, "title": "BRIEF-Chiasma Announces FDA Agreement To Redefine Certain Secondary Endpoints In Phase 3 Clinical Trial", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "chiasma inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 14 (Reuters) - Chiasma Inc:\n* CHIASMA ANNOUNCES FDA AGREEMENT TO REDEFINE CERTAIN SECONDARY ENDPOINTS IN CHIASMA OPTIMAL PHASE 3 CLINICAL TRIAL\n* CHIASMA - FOURTH, FIFTH SECONDARY ENDPOINTS IN PHASE 3 TRIAL NOW BEEN REDEFINED TO DESCRIPTIVE STATISTICS MEASURED WITHIN EACH TREATMENT GROUP\n* CHIASMA INC - UNDER SPA AGREEMENT MODIFICATION FOR CHIASMA OPTIMAL PHASE 3 TRIAL, BETWEEN-ARM COMPARISONS OF 2 DESCRIPTIVE MEASURES WILL NOT BE MADE\n* CHIASMA INC - FDA INDICATED IT PLANS TO CONSIDER SECONDARY ENDPOINTS IN ITS EVALUATION OF TOTALITY OF EVIDENCE OF ORAL OCTREOTIDEâ€™S TREATMENT EFFECT Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-15T04:23:00.000+03:00", "crawled": "2018-05-15T13:58:08.057+03:00", "highlightTitle": ""}